ABO Blood Groups and susceptibility to covid19 in African Population

Main Article Content

Abibatou SALL Baye Diam SANON Mba Bamboo DIAKHABY Assane DRAME Diama SAMB Louise FORTES Moussa SECK Blaise Félix Faye Awa Oumar TOURE Saliou DIOP



SARS-CoV-2 infection is characterized by high contagiousness, morbidity and mortality which are accompanied by various biological changes, particularly hematological changes. Its association with blood groups has been revealed by several authors. Our overall goal was to find a link between ABO blood groups and COVID-19 in African population

Patients and Methods

We conducted a prospective, descriptive and analytical study carried out in the epidemic treatment center and the hematology laboratory of the Dalal Jamm hospital in Dakar. All patients aged over 18 years, and tested positive for SARS-CoV-2 infection by molecular biology, were included. Clinical data was provided by attending physicians.

The complete blood count was performed on NX1500 (Sysmex Japan) and blood grouping was done on the Ortho device (Ortho, Clinical Diagnostic, USA).

The data were compiled using the Microsoft Excel. Statistical analyses were performed on SPSS. The confidence interval of 95% was used for the estimations and statistical tests were considered significant when the p-value was below 0.05


A total of 259 patients were recruited including 157 males and 102 females with a mean age of 56.7 years. The comorbidities were dominated by high blood pressure (28.46%) and diabetes (13.08%). The non-severe forms represented almost three-quarters of our population. The distribution of ABO groups in our population showed a predominance of group O (49.57%) followed by groups A (28.21%), B (17.09%) and AB (5.13%) (O> A> B> AB). This same formula was found in our reference sample. However, blood group A was more represented in our population compared to that of reference with a difference at the limit of significance (p = 0.055). Regarding blood groups according to clinical forms, we found that group A had twice the risk of developing a severe form [OR = 1.95; CI = 1.06-3.57; p-0.032] while the O group would be protective [OR = 0.76; CI = 0.59-0.89; p-0.02]. This trend was however lost on multivariate analysis.


Our study revealed that blood group A was linked to the severity of COVID-19 but this result remains to be confirmed with much larger sampling.

Article Details

How to Cite
SALL, Abibatou et al. ABO Blood Groups and susceptibility to covid19 in African Population. Medical Research Archives, [S.l.], v. 10, n. 1, feb. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2689>. Date accessed: 28 nov. 2022. doi: https://doi.org/10.18103/mra.v10i1.2689.
Research Articles


1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–13.

2. Mughal MS, Kaur IP, Jaffery AR, Dalmacion DL, Wang C, Koyoda S, et al. COVID-19 patients in a tertiary US hospital: Assessment of clinical course and predictors of the disease severity. Respir Med. 2020; 172: 106-130.

3. Fan Q, Zhang W, Li B, Jia-Li D, Zhang J, Zhao F. Association Between ABO Blood Group System and COVID-19 Susceptibility in Wuhan. Front Cell Infect Microbiol 2020; 10:404

4. GökerH, Karakulak EA, Demiroglu H, Ceylan CMA, Buyukasik Y, Inkaya ACI et al. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome. Turk J Med Sci. 2020; 50(4):679-683

5. Hoiland RL, Fergusson NA, Mitra AR, Griedale DEG, Devine DV, Stukas S et al. The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. Blood Adv 2020; 4(20): 4981-4989.

6. Latz CA, DeCarlo C, Maximilian CY, Patell R, Conrad MF, Eagleton M et al. Blood type and outcomes in patients with COVID-19. Ann Hematol. 2020; 99:2113–2118

7. Ray JG, Schul MJ, Vermeulen MJ, Park AL. Association Between ABO and Rh Blood Groups and SARS-CoV-2 Infection or Severe COVID-19 Illness. Ann Intern Med. 2021 ;174 :308–315.
8. Fogarty H, Townsend L, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Browne P, et al. More on COVID-19 coagulopathy in Caucasian patients. Br J Haematol. 2020;189(6):1060‑1.

9. Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 202;58(7):1021-1028

10. Alarcon CGT, Ruiz AG, Ibanez CRC, Pagoda IIM, Arce CMM, Dominguez BEC et al. Blood system ABO antigens as risk factor for severity of SARS-CoV-2 infection. Gac Med Mex 2021;157(2):174-180.

11. Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020;7(9):671‑8.

12. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020 ;323(16):1574-1581.

13. Jin JM, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Health. 2020;8:152.

14. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;e3319.

15. Barnkob MB, Pottegård A, Støvring H, Haunstrup TM, Homburg K, Larsen R et al. Reduced prevalence of SARS-CoV-2 infection in ABO blood group O. DOI 10.1182/bloodadvances.2020002657

16. Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X et al. Relationship Between the ABO Blood Group and the Coronavirus Disease 2019 (COVID-19) Susceptibility. Clin Infect Dis 2021;73(2):328-331

17. Padhi S, Suvankar S, Dash D, Panda VK, Pati A, Panigrahi J et al. ABO blood group system is associated with COVID-19 mortality: An epidemiological investigation in the Indian population. Transfus Clin Biol 2020 ; 27(4) :253-258

18. Latz C, DeCarlo C, Boitano L, Maximillin Png CY,Patell R et al. Blood type and outcomes in patients with COVID-19. Ann Hematol 2020;99(9):2113-2118.

19. Guillon P, Clement M, Sébille V, Rivain JG, Chou CF, Clouet NR et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology.2008 ;18(12):1085-93

20. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565-574